Article
Plant Sciences
Kaichun Wang, Wei Liu, Qinfen Xu, Chao Gu, Daode Hu
Summary: This study found that Tenacissoside G (TG) exhibited dose-dependent growth inhibitory activity and cell cycle arrest induction in colorectal cancer cells, enhancing the anticancer effects of 5-fluorouracil (5-FU). The synergistic effects may be attributed to increased activation of caspase cascade, enhancement of DNA damage, and induction of p53 phosphorylation at Serine 46.
Article
Materials Science, Multidisciplinary
Dhanya Moorkoth, Kesavan Madhavan Nampoothiri, Selvaraj Nagarajan, Aswathy Ravindran Girija, Sivakumar Balasubramaniyan, D. Sakthi Kumar
Summary: Star-shaped polylactide nanoparticles were designed and synthesized for achieving apoptosis through synergistic dose-dependent delivery. These nanoparticles showed excellent encapsulation and loading efficiency, with time-dependent release in acidic pH. The results demonstrated high cytotoxicity of the nanoparticles towards colon cancer cells, while remaining non-toxic to normal cells.
ACS APPLIED POLYMER MATERIALS
(2021)
Article
Medicine, Research & Experimental
Nisreen H. Shehatta, Tarek M. Okda, Gamal A. Omran, Mohammad M. Abd-Alhaseeb
Summary: The study found that pre-treatment with baicalin and treatment with baicalin and/or 5-FU significantly reduced inflammation and angiogenesis while increasing apoptotic cell death.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Biochemistry & Molecular Biology
Hyocheol Bae, Woonghee Lee, Jisoo Song, Taeyeon Hong, Myung Hyun Kim, Jiyeon Ham, Gwonhwa Song, Whasun Lim
Summary: The study found that polydatin can suppress the progression of colon cancer, induce anti-cancer effects by modifying cell cycle distribution and causing mitochondrial dysfunction. It can also overcome drug resistance by inhibiting signaling pathways and enhancing chemosensitivity, potentially serving as an innovative medicinal drug for colon cancer treatment.
Article
Chemistry, Medicinal
Yasmine Radwan, Kholoud K. Arafa, Monira G. Ghoniem, Eida S. Al-Farraj, Ibrahim M. El-Sherbiny
Summary: This study aimed to investigate the synergistic therapeutic effect of the novel combination of capsaicin and 5-fluorouracil encapsulated in lipid nanocapsules. The results showed that the developed nanoformulations had good physical stability and exhibited superior antiproliferative effect compared to the free drugs.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
(2023)
Article
Pharmacology & Pharmacy
Han Hao, Yao Zhang, Xiaoxiao Hu, Wei Guo, Caiqin Yang, Jing Wang
Summary: Gallic acid (GA) has been found to have anti-tumor activity. A novel cocrystal hydrate of 5-fluorouracil (5-FU-GA-H2O) was successfully screened and characterized, and it exhibited synergistically enhanced anti-tumor activity. The cocrystal also showed improved membrane permeability, oral bioavailability, and cytotoxicity against breast cancer cells.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Jutao Li, Junqin Xu, Yuxin Sun, Ruolan Fu, Dan Ye
Summary: The study investigates the combinatorial anti-proliferative efficacy of biochanin A (BCA) and sulforaphane (SFN) against MCF-7 breast cancer cells. The results show that the combination of BCA and SFN exhibits inhibitory activity against cancer cells, with increased apoptogenic activity and ROS production. Furthermore, BCA and SFN down-regulate the ERK-1/2 signaling pathway, inducing apoptosis in cancer cells. Thus, BCA and SFN co-treatment could be a promising therapeutic target for breast cancer.
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
(2023)
Article
Oncology
Nkafu Bechem Ndemazie, Andriana Inkoom, Dexter Ebesoh, Raviteja Bulusu, Esther Frimpong, Jose Trevino, Bo Han, Xue Zhu, Edward Agyare
Summary: In this study, MFU was synthesized and characterized, showing potential anticancer activity against pancreatic cancer (PCa). The inhibitory concentration of MFU was significantly lower than that of Gemcitabine hydrochloride (GemHCl) in both cell lines, indicating its potential as a new therapeutic option for PCa.
Article
Biochemistry & Molecular Biology
Ching-Feng Wu, Ching-Yang Wu, Robin Y. -Y. Chiou, Wei-Cheng Yang, Chuen-Fu Lin, Chao-Min Wang, Po-Hsun Hou, Tzu-Chun Lin, Chan-Yen Kuo, Geng-Ruei Chang
Summary: The study showed that the treatment with Zotarolimus or Zotarolimus combined with 5-FU significantly inhibited lung adenocarcinoma growth, increased tumor cell apoptosis, reduced inflammation levels, and inhibited tumor metastasis. The synergistic anti-tumor effect of Zotarolimus and 5-FU on lung adenocarcinoma was evident, with the combination treatment being more effective than using 5-FU or Zotarolimus alone.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Physical
Jaya R. Lakkakula, Rui Werner Macedo Krause, Deepika Divakaran, Sagar Barage, Rohit Srivastava
Summary: The circulation time and solubility of 5-Fluorouracil have been prolonged and increased by complexing it with cyclodextrin and conjugating it onto gold nanoparticles to form 5Fu ICAu. The 5Fu-ICAu system showed higher cell inhibition rate on breast cancer cell lines due to the enhanced EPR effect allowing selective accumulation of nanoparticles at tumor sites.
JOURNAL OF MOLECULAR LIQUIDS
(2021)
Article
Pathology
Yu-Ling Qu, Xiao-Li Liu, Shan-Yu Zhao, Xue-Feng Zhai
Summary: This study found that SPOCK1 is upregulated in 5-FU-resistant CRC cells and that knockdown of SPOCK1 increases their sensitivity to 5-FU. Conversely, overexpression of SPOCK1 enhances CRC cell resistance to 5-FU and reduces cell apoptosis.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Medicine, Research & Experimental
Rinad A. Algehani, Raefa Abou Khouzam, Gehan A. Hegazy, Aliaa A. Alamoudi, Ali M. El-Halawany, Riham S. El Dine, Ghada A. Ajabnoor, Fahad A. Al-Abbasi, Mohammed A. Baghdadi, Ibrahim Elsayed, Masao Hattori, Ahmed M. Al-Abd
Summary: A synergistic effect in terms of anticancer properties was observed when colossolactone-G was combined with 5-FU and GCB, influencing both apoptosis and autophagic cell death mechanisms.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Medicine, Research & Experimental
Michal Hendrych, Kamila Rihova, Barbora Adamova, Vojtech Hradil, Marek Stiborek, Petr Vlcek, Marketa Hermanova, Jana Vasickova, Petr Benes, Jan Smarda, Viktor Kanicky, Jan Preisler, Jarmila Navratilova
Summary: This study utilized robust three-dimensional models to test novel therapeutic strategies and proposed the combined therapy of 5-fluorouracil and disulfiram/copper for further research in colorectal carcinoma treatment. It also demonstrated that organotypic cultures are suitable models for anti-cancer drug testing.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Biology
Norah M. Alhoshani, Norah S. Al-Johani, Nora Alkeraishan, Saud Alarifi, Saad Alkahtani
Summary: Colon cancer is a common malignancy and there is a need for improving the quality of life for patients. This study explored the role of lycopene as an adjuvant therapy with 5-fluorouracil (5-FU) in colon cancer cells. The findings showed that lycopene enhanced apoptosis, suppressed cell migration, and reduced cytotoxicity when combined with 5-FU treatment.
SAUDI JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Review
Pharmacology & Pharmacy
Xia Li, Yan Ma, Junzhou Wu, Maowei Ni, Aiping Chen, Yun Zhou, Wumin Dai, Zhongjian Chen, Ruibin Jiang, Yutian Ling, Qinghua Yao, Wei Chen
Summary: 5-Fluorouracil (5-Fu) is a first-line drug for colorectal cancer (CRC) therapy. However, the development of 5-Fu resistance limits its effectiveness and leads to poor prognosis. Transglutaminase 2 (TGM2) is associated with chemoresistance in CRC and is regulated by thiol oxidative stress. Upregulation of thiol oxidative stress reverses 5-Fu resistance through downregulation of TGM2 and enhances apoptosis. TGM2 may serve as a potential therapeutic target for treating 5-Fu-resistant CRC.
DRUG RESISTANCE UPDATES
(2023)
Article
Pharmacology & Pharmacy
Samar H. Gerges, Mai F. Tolba, Doaa A. Elsherbiny, Ebtehal El-Demerdash
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
(2020)
Review
Oncology
Mai F. Tolba
INTERNATIONAL JOURNAL OF CANCER
(2020)
Article
Neurosciences
Marwa A. Ali, Esther T. Menze, Marianne G. Tadros, Mai F. Tolba
Article
Biochemistry & Molecular Biology
Shifaa M. Abdin, Mai F. Tolba, Dana M. Zaher, Hany A. Omar
Summary: The inhibition of NF-kappa B activity can enhance the sensitivity of breast cancer cells to chemotherapy, particularly doxorubicin, by modulating multidrug resistance. Combined treatment with NF-kappa B inhibitors can sensitize resistant breast cancer cells to doxorubicin, by suppressing NF-kappa B activation and downregulating MDR efflux transporters.
CHEMICO-BIOLOGICAL INTERACTIONS
(2021)
Review
Oncology
M. F. Tolba, H. Elghazaly, E. Bousoik, M. M. A. Elmazar, S. M. Tolaney
Summary: The focus is on testing the effectiveness of immunotherapy combined with other drugs to enhance the response of breast cancer patients to immunotherapy. Different combination therapy strategies are showing promising signals to increase the chances of benefit for breast cancer patients.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Sarah A. Baraka, Mai F. Tolba, Doaa A. Elsherbini, Reem N. El-Naga, Azza S. Awad, Ebtehal El-Demerdash
Summary: Rosuvastatin and low-dose carvedilol combined therapy provides better protection against myocardial infarction compared to monotherapy, potentially through the activation of PI3K/Akt/Nrf2/HO-1 pro-survival signalling pathway.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
(2021)
Review
Medicine, General & Internal
Kingsley Badu, Kolapo Oyebola, Julien Z. B. Zahouli, Adeniyi Francis Fagbamigbe, Dziedzom K. de Souza, Natisha Dukhi, Ebenezer F. Amankwaa, Mai F. Tolba, Augustina A. Sylverken, Lydia Mosi, Priscilla Kolibea Mante, Damaris Matoke-Muhia, Nowsheen Goonoo
Summary: The evolving nature of SARS-CoV-2 requires periodic revisions of COVID-19 patient treatment and discharge guidelines. The WHO plays a crucial role in handling country-level pandemic preparedness and patient management protocols. Patients can be released from isolation centers on the 10th day following clinical symptom manifestation, with at least 72 additional hours following the resolution of symptoms.
FRONTIERS IN MEDICINE
(2021)
Review
Oncology
Nada K. Sedky, Alyaa A. Hamdan, Salma Emad, Aya L. Allam, Mohamed Ali, Mai F. Tolba
Summary: Solid tumors, such as skin, lung, breast, colon, and prostate cancers, pose a significant challenge in treatment, especially in advanced/metastatic cases. Targeting the PD-1/PD-L1 immune checkpoint has been studied extensively as a new approach to managing these hard-to-treat cancers. However, monotherapy with immunotherapies has shown low response rates and resistance, necessitating the development of combination regimens with other immune modulatory agents. Epigenetic modifiers, such as HDACIs, have shown promising effects in modulating the tumor microenvironment and host immune cells, making them attractive candidates for combination testing with immunotherapy.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Christine N. Habib, Mohamed R. Mohamed, Mariane G. Tadros, Mai F. Tolba, Esther T. Menze, Somia Masoud
Summary: The study found that diosmin (DM) has neuroprotective effects in Parkinson's disease (PD) and can act through various mechanisms such as anti-inflammatory and antioxidative properties. These findings suggest that DM may be a promising candidate for managing the neuropathological course of PD.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Editorial Material
Oncology
Mai F. Tolba, Cesar A. Santa-Maria, Adriana Albini, Emile R. Chimusa, Basel K. Al-Ramadi, Sara M. Tolaney
FRONTIERS IN ONCOLOGY
(2021)
Editorial Material
Pharmacology & Pharmacy
Husain Yar Khan, Khuloud Bajbouj, Mai F. Tolba
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
Adeniyi Francis Fagbamigbe, Mai F. Tolba, Ebenezer F. Amankwaa, Priscilla Kolibea Mante, Augustina Angelina Sylverken, Julien Z. B. Zahouli, Nowsheen Goonoo, Lydia Mosi, Kolapo Oyebola, Damaris Matoke-Muhia, Dziedzom K. de Souza, Kingsley Badu, Natisha Dukhi
Summary: This article assesses the realities and pros and cons of the WHO COVID-19 interim guidance in Africa and discusses the known peculiarities of the continent. The findings provide important links between sub-themes that may impact the containment and management of COVID-19 cases in Africa.
SCIENTIFIC AFRICAN
(2022)
Article
Public, Environmental & Occupational Health
Lydia Mosi, Augustina Angelina Sylverken, Kolapo Oyebola, Kingsley Badu, Natisha Dukhi, Nowsheen Goonoo, Priscilla Kolibea Mante, Julien Zahouli, Ebenezer Forkuo Amankwaa, Mai Fathy Tolba, Adeniyi Francis Fagbamigbe, Dziedzom Komi de Souza, Damaris Matoke-Muhia
Summary: The COVID-19 pandemic has posed significant challenges globally, with the importance of rapid and effective testing for suspected cases highlighted by the World Health Organization. While various testing methods have been developed, limited testing options, equipment, and trained personnel in many African countries are hindering efforts to combat the pandemic effectively.
PAN AFRICAN MEDICAL JOURNAL
(2021)
Meeting Abstract
Oncology
Shifaa M. Abdin, Mai F. Tolba, Dana M. Zaher, Hany A. Omar
